Pituitary adenylate cyclase activating polypeptide stimulates release of peptide YY. 1993

T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
Department of Surgery, University of Texas Medical Branch, Galveston 77555.

The purpose of these experiments was to examine the effects of the recently discovered gastrointestinal peptide, pituitary adenylate cyclase activating polypeptide (PACAP), and two structurally related peptides, vasoactive intestinal polypeptide and secretin, on release of peptide YY (PYY) in conscious dogs. Intravenous administration of PACAP-27 or -38 stimulated a dose-related release of PYY; PACAP-27 was more potent than PACAP-38. PACAP-stimulated release of PYY was inhibited significantly by atropine, whereas ganglionic or beta-adrenergic blockade with hexamethonium and propranolol treatment, respectively, did not affect PACAP-induced release of PYY significantly (P > 0.05). These results indicate that PACAP-induced release of PYY is cholinergic dependent and that beta-adrenergic tone and ganglionic transmission do not participate in PACAP-induced release of PYY. PACAP may play a role in the neural regulation of PYY release.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D009479 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. Neuropeptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011433 Propranolol A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. Dexpropranolol,AY-20694,Anaprilin,Anapriline,Avlocardyl,Betadren,Dociton,Inderal,Obsidan,Obzidan,Propanolol,Propranolol Hydrochloride,Rexigen,AY 20694,AY20694,Hydrochloride, Propranolol
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005730 Ganglionic Blockers Agents having as their major action the interruption of neural transmission at nicotinic receptors on postganglionic autonomic neurons. Because their actions are so broad, including blocking of sympathetic and parasympathetic systems, their therapeutic use has been largely supplanted by more specific drugs. They may still be used in the control of blood pressure in patients with acute dissecting aortic aneurysm and for the induction of hypotension in surgery. Ganglionic Blocking Agents,Ganglioplegic Agents,Blocking Agents, Ganglionic,Ganglionic Blockaders,Agents, Ganglionic Blocking,Agents, Ganglioplegic,Blockaders, Ganglionic,Blockers, Ganglionic
D006584 Hexamethonium Compounds Compounds containing the hexamethylenebis(trimethylammonium) cation. Members of this group frequently act as antihypertensive agents and selective ganglionic blocking agents. Compounds, Hexamethonium

Related Publications

T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
June 1993, Neuroendocrinology,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
December 1998, Annales d'endocrinologie,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
August 1992, Gastroenterology,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
January 2004, Current pharmaceutical design,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
January 1992, Life sciences,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
September 1992, Endocrinology,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
November 1992, Regulatory peptides,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
September 1997, The Journal of clinical endocrinology and metabolism,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
September 1996, The American journal of physiology,
T Zhang, and G Gomez, and N Yanaihara, and T Mochizuki, and J C Thompson, and G H Greeley
January 1996, Peptides,
Copied contents to your clipboard!